Combining Varenicline and Naltrexone for Smoking Cessation
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This study is a double-blind, randomized clinical trial using a two group medication design
consisting of the combination of VAR (1 mg twice daily) + NTX (50 mg once daily) and VAR (1
mg twice daily) + PLA (matched to NTX), for smoking cessation in a sample of heavy drinking
daily smokers who want to quit smoking and reduce drinking.